Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnurag Relan - CMOFabrice Chouraqui - CEOJoseph Pantginis - Managing Director, Equity ResearchKenneth Lynard - CFOLaVerne Marsh - Chief Commercial OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior AnalystLucy Codrington - Research AnalystNatalia Webster - AnalystSheila Hernandez - AnalystSimon Scholes - Senior AnalystOperatorGood day, thank you for standing by. Welcome to the Pharmi ...

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnurag Relan - CMOFabrice Chouraqui - CEOJoseph Pantginis - Managing Director, Equity ResearchKenneth Lynard - CFOLaVerne Marsh - Chief Commercial OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior AnalystLucy Codrington - Research AnalystNatalia Webster - AnalystSheila Hernandez - AnalystSimon Scholes - Senior AnalystOperatorGood day, thank you for standing by. Welcome to the Pharmi ...

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Speaker8Good day, thank you for standing by. Welcome to the Pharming Group N.V. fourth quarter and full year 2025 financial results conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, please press star one one on your telephone. You will then hear an automated message advising yo ...

Summary of Pharming Group FY Conference Call Company Overview - **Company**: Pharming Group (NasdaqGM:PHAR) - **Date of Conference**: February 25, 2026 - **Key Participants**: Anurag Relan (Chief Medical Officer), Kenneth Lynard (CFO), Michael Levitan (IR team) Core Points and Arguments Financial Performance - **2025 Sales**: $376 million, representing a **27% growth** compared to 2024 [6] - **2026 Revenue Guidance**: Expected to be between **$405 million and $425 million**, indicating an **8%-13% growth** [7] - **Operating Expenses for 2025**: Projected to be between **$304 million and $308 million** [7] - **Operating Profit**: Generated **$30 million** in operating profit for the first nine months of the year [8] - **Operating Cash Flow**: Achieved **$44 million** in operating cash flow [8] Product Highlights - **RUCONEST**: - Approved for treating acute attacks of hereditary angioedema (HAE) and has been in the market for about **10 years** [4] - Unique value proposition as the only recombinant C1 inhibitor replacement therapy [9] - Demonstrated efficacy with **97%** of attacks treated successfully in clinical trials [10] - Sustained response in **93%** of treated attacks lasting at least three days [10] - **Joenja**: - Launched in 2023 for treating activated PI3K delta syndrome (APDS) [5] - Considered a significant growth catalyst with potential for higher prevalence than previously observed [5] - Ongoing Phase II trials for leniolisib in new indications [5] - **Napazimone (formerly KL1333)**: - Targeting primary mitochondrial disease with a significant patient population of over **30,000** diagnosed in the U.S. and Europe [21] - Phase 2 program underway with positive interim analysis indicating potential for disease-modifying treatment [22] Strategic Developments - **Acquisition of Abliva**: Enhances the pipeline with KL1333 (napazimone) making good progress in trials [5] - **Commercial Strategy**: Pharming has withdrawn from commercial activities related to RUCONEST outside the U.S. but retains infrastructure to support Joenja's growth in Europe [40] - **Business Development**: Active scouting for in-licensing and M&A opportunities to enhance the pipeline [42] Additional Important Information - **Regulatory Updates**: - Received a Complete Response Letter for the supplemental NDA application to expand Joenja's use to pediatric patients aged 4-11 [26] - Anticipated approval from EMA in March, with potential approval in Japan later this year [27] - **Clinical Trials**: - Two Phase II proof-of-concept studies for Joenja expected to read out in the second half of the year [27] - Napazimone study (FALCON Study) enrolling **180 patients** with results expected by the end of next year [25] - **Market Position**: Pharming aims to develop into a leading global rare disease company with a diverse portfolio and strong market presence [6] This summary encapsulates the key points discussed during the Pharming Group FY Conference Call, highlighting the company's financial performance, product developments, strategic initiatives, and regulatory updates.

Core Insights - Pharming is presenting its financial guidance for the year and highlighting its clinical stage pipeline programs during the 2026 Investor Day [1][2] - The company has evolved from a single asset company to a fast-growing biotech with two commercial assets experiencing double-digit growth and a late-stage pipeline with two programs each having over $1 billion sales potential [3] Financial Update - A short business and financial update will be provided, focusing on the financial guidance for the year [2] - The company emphasizes its growth trajectory and the potential of its pipeline programs [3] Pipeline Overview - The presentation will include two longer sessions dedicated to the pipeline, specifically on leniolisib for high prevalence primary immunodeficiencies (PIDs) and KL1333, napazimone [2]